CTOs on the Move

Forest Pharmaceuticals Inc

www.forestpharm.com

 
Forest Pharmaceuticals Inc is a Earth City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Journey Medical

Journey’s purpose is to positively impact people by providing effective solutions for treating skin conditions, healing wounds, and supporting healthy skin.

Pharmatech Associates

Staffed by industry experts, Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech`s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Manufacturing—including development, Compliance, Regulatory, and Validation. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area. Our Culture: At Pharmatech Associates, our mission is to fulfill customer expectations throughout the development and execution of tailored, high value, innovation solutions. We are committed to fostering an environment that is professional and forth right. These principles are captured in the values we believe are essential to maintaining our supportive culture and our commitment to our clients` success. We seek to establish an atmosphere of openness, objectivity, accountability, mutual respect and teamwork so each employee can realize their fullest potential for personal and professional growth. We value work life balance. At Pharmatech talent matters, and we tackle each project with a “no fear” attitude. We stand together as a team, and we`ve got your back. Pharmatech`s commitment to integrity is unwavering.

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.